Eurofins Genomics Will Be Conducting Genotyping for up to 5 Million Participants of Our Future Health, UK’s Largest Ever Health Research Programme
March 08 2022 - 6:01AM
Business Wire
Eurofins (Paris:ERF):
Eurofins Genomics is proud to announce its support for Our
Future Health, the UK’s largest ever health research programme.
Eurofins Genomics will be genotyping five million consenting
participants within Our Future Health. This will provide important
data that, when combined with other questionnaire and health
information, will generate a comprehensive picture of population
health in the UK, insights from which will be used to transform the
prevention, detection and treatment of diseases.
Our Future Health is the UK’s largest health research programme
ever conducted, bringing together the public, charity and private
sectors to research disease at an unprecedented scale in the
UK.
As one of Europe’s leading providers of genomics services,
Eurofins Genomics will conduct the genotyping for the Our Future
Health programme. To deliver this service, Eurofins Genomics will
establish a dedicated laboratory in the UK, where it will carry out
genotyping to identify genetic variations and combinations. Genetic
variations such as changes of single building blocks of the DNA are
associated with many known diseases. Eurofins Genomics will utilise
specifically designed microarray technology with high accuracy and
reproducibility to identify hundreds of thousands of genetic
variations at a time. The resulting data will then be used to
determine disease risks and discover biomarkers for diseases
diagnosis and therapeutics.
The goal of the Our Future Health programme is to facilitate the
discovery and development of new methods of prevention, early
detection and treatment of a wide range of diseases.
Today, 59% of UK citizens aged 65 years or older have two or
more serious health conditions, and this statistic has been
projected to reach 70% by 2035. With the recruitment of five
million adult volunteers, this research programme has the potential
to improve the long-term health of millions of people in the UK and
globally. The insights gained into links between DNA and diseases
through this programme will accelerate the development of
innovative solutions to help people to live healthier lives for
longer.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 58,000 staff across a network
of 900 laboratories in 54 countries, Eurofins’ companies offer a
portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308005687/en/
For further information: Julian Schloßmacher Head of
Marketing and Communication Eurofins Genomics Europe
julianschlossmacher@eurofins.com https://ourfuturehealth.org.uk/
https://eurofinsgenomics.com
Eurofins Scientific (EU:ERF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Eurofins Scientific (EU:ERF)
Historical Stock Chart
From Aug 2023 to Aug 2024